Drug Trial Radar · NCT07193511
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
355
Planned (sponsor's estimate)
Start
Oct 2, 2025
Primary completion
Mar 2030
Study completion Sep 2030
Sponsor
- Lead sponsor
- Avenzo Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.
Conditions
- Solid Tumor Cancer
- Locally Advanced
- Metastatic Solid Tumors
- Urothelial Cancer
Interventions
AVZO-103Drug
Specific dose in protocol specified schedule
Combination AgentDrug
Per label based on combination agent used
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)Time frame: Approximately 2 years
- Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1)Time frame: Approximately 16 months
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)Time frame: From baseline until end of study treatment or study completion (approximately 2 years)
- Objective Response Rate (ORR) (Phase 2)Time frame: From baseline through disease progression or study completion (approximately 2 years)
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Avenzo Therapeutics Recruiting Site
San Francisco, California · Recruiting
Avenzo Therapeutics Recruiting Site
Aurora, Colorado · Recruiting
Avenzo Therapeutics Recruiting Site
New Haven, Connecticut · Recruiting
Avenzo Therapeutics Recruiting Site
Orlando, Florida · Recruiting
Avenzo Therapeutics Recruiting Site
Tampa, Florida · Recruiting
Avenzo Therapeutics Recruiting Site
Boston, Massachusetts · Recruiting
Avenzo Therapeutics Recruiting Site
New York, New York · Recruiting
Avenzo Therapeutics Recruiting Site
Chapel Hill, North Carolina · Recruiting
Avenzo Therapeutics Recruiting Site
Cleveland, Ohio · Recruiting
Avenzo Therapeutics Recruiting Site
Oklahoma City, Oklahoma · Recruiting
Avenzo Therapeutics Recruiting Site
Myrtle Beach, South Carolina · Recruiting
Avenzo Therapeutics Recruiting Site
Nashville, Tennessee · Recruiting
Avenzo Therapeutics Recruiting Site
Austin, Texas · Recruiting
Avenzo Therapeutics Recruiting Site
Houston, Texas · Recruiting
Avenzo Therapeutics Recruiting Site
Irving, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.